Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients

Gynecologic Oncology

Volumn 66, Issue 2, 1997, Pages 233-237

  Cheng, Wen Fang ^a   Lin, Ho Hsiung ^a   Torng, Pao Ling ^a   Huang, Su Cheng ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CONTROLLED STUDY; CURETTAGE; DIABETES MELLITUS; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERMENORRHEA; HYSTEROSCOPY; MAJOR CLINICAL STUDY; MENARCHE; NULLIPARA; POLYP; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; THYROID DISEASE; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING;

EID: 0031214148     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4739     Document Type: Article

References (22)

1. Bartlett K, Ermin O, Hutcheon A, Preece P, Scott J S, Forrest P, Chetty U, Prescott R J, Rodger A, Smyth J, George D, Habeshaw T, Kaye S B, McArdle C S, McCallum M, Smith D C, McMillan B, Robinson S M, Stewart H J, White G K, Giles G R. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet. 2:1987;171-175.
2. Fisher B, Costantino J, Redmond L, Poisson R, Bowman D, Couture J, Dimitrov N V, Wolmark N, Wickerham D L, Fisher E R, Margolese R, Robioux A, Shibata H, Terz J, Paterson A HG, Feldman M I, Farrer W, Evans J, Lickley H L, Ketner M. A randomized, clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 320:1989;479-484.
3. Baum M, Brinkley D M, Dosset J A. Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Br J Cancer. 57:1988;609-611.
4. Boccardo F, Guarnieri D, Rubagotti A, Casertelli G L, Bentivoglio G, Conte N, Campanella G, Gaggaro G, Comalli G, Zanardi S, Nicolo G. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori. 70:1984;61-68.
5. Jordan V C. A current view of tamoxifen for treatment and prevention of breast cancer. Br J Pharmacol. 110:1993;507-517.
6. Cohen I, Rosen D JD, Shapira J, Cordoba M, Gilboa S, Altaras M M, Yigael D, Beyth Y. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol. 100:1993;567-570.
7. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen P J, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 81:1993;660-664.
8. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri (letter). Lancet. 3:1988;563.
9. Andersson M, Storm H H, Mouridsen H T. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. J Natl Cancer Inst. 31:1992;259-263.
10. Sunderland M C, Osborne C K. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 9:1991;1283-1297.
11. Fisher B, Costantino J P, Redmond C K, Fisher E R, Wickerham D L, Cronin W M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J Natl Cancer Inst. 86:1994;527-537.
12. Leeuwen F E, Benraadt J, Coebergh J WW, Kiemeney L A, Gimbrere C H, Otter R, Schouten L J, Damhuis R A, Bontenbal M, Diepenhorst F W, van den Belt-Dusebout A W, van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343:1994;448-452.
13. Fornander T, Rutquist L E, Cedarmark B, Mattsson A, Skoog L, Theve T. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1:1989;117-120.
14. 3. Mol Cell Endocrinol. 8:1977;179-188.
15. Archer D F, McIntyre-Seltman K, Wilborn W W, Dowling E A, Cone F, Creasy G W, Kafrissen M E. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol. 165:1991;317-322.
16. Cohen I, Rosen D JD, Shapira J, Cordoba M, Gilboa S, Altaras M M, Yigael D. Endometrial change with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol. 52:1994;185-190.
17. Lin H H, Wu M Y, Shyu M K, Chen D, Tsai J L, Hsieh C Y. Clinical study of 381 postmenopasual bleeding patients. J Formosan Med Assoc. 92:1993;41-44.
18. Kistner R W. Treatment of hyperplasia and carcinoma in situ of endometrium. Clin Obstet Gynecol. 5:1982;63-72.
19. Cohen I, Rosen D JD, Tepper R, Cordoba M, Shapira Y, Altaras M M, Yigael D, Beyth Y. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients with tamoxifen. J Ultra Med. 5:1993;275-280.
20. Nasari M N, Coast G J. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol. 96:1989;133-138.
21. Goldstein S R, Nachtigall M, Snyder J R, Nachtigall L. Endometrium assessed by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol. 163:1990;119-123.
22. Yokosuka K, Teshima H, Katase K, Fujimoto I, Yamauchi K, Hasumi K, Tatsuki Y. Effects of long-term administration of tamoxifen on vaginal epithelium and complications of endometrial lesions in breast cancer patients. Acta Obstet Gynaecol Jpn. 47:1995;125-132.